Investments
15Portfolio Exits
1Funds
2Latest Novalis LifeSciences News
Jul 31, 2022
Molecules, Raises $70M 1d agoVenture CapitaldailyaltsViews: 4 Enko announced its $70 million Series C funding round led by agrochem company Nufarm with participation by Anterra Capital, Taher Gozal, the Bill & Melinda Gates Foundation, Eight Roads Ventures, Finistere Ventures, Novalis LifeSciences, Germin8 Ventures, TO Ventures Food, Endeavor8, Alumni Ventures Group and Rabo Food & Agri Innovation Fund. Not a member yet? Free Membership for Qualified Investors and Industry Participants Easily Customize Content to Match Your Investment Preferences Breaking News 24/7/365 Alternative Investment Listings & LeaderBoards Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets,Presentations, Investment Mandates, Video PitchBooks & More! Company Directory AUM Accelerator Program (designed for investment managers) Over 450K+ Industry Headlines, Posts and Updates ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY.CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN.PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS.THIS IS NOT A SOLICITATION FOR INVESTMENT.THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY.IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES.ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM.PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT. ALPHAMAVEN
Novalis LifeSciences Investments
15 Investments
Novalis LifeSciences has made 15 investments. Their latest investment was in Animol Discovery as part of their Series B on July 7, 2022.
Novalis LifeSciences Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
7/28/2022 | Series B | Animol Discovery | $34M | Yes | 2 | |
7/27/2022 | Series C | Enko Chem | $70M | No | 4 | |
5/5/2022 | Series C | Vizgen | $85.2M | No | 3 | |
3/8/2022 | Series B | |||||
1/18/2022 | Series B |
Date | 7/28/2022 | 7/27/2022 | 5/5/2022 | 3/8/2022 | 1/18/2022 |
|---|---|---|---|---|---|
Round | Series B | Series C | Series C | Series B | Series B |
Company | Animol Discovery | Enko Chem | Vizgen | ||
Amount | $34M | $70M | $85.2M | ||
New? | Yes | No | No | ||
Co-Investors | |||||
Sources | 2 | 4 | 3 |
Novalis LifeSciences Portfolio Exits
1 Portfolio Exit
Novalis LifeSciences has 1 portfolio exit. Their latest portfolio exit was Biotalys on July 01, 2021.
Novalis LifeSciences Fund History
2 Fund Histories
Novalis LifeSciences has 2 funds, including Novalis LifeSciences Investments II.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
12/8/2021 | Novalis LifeSciences Investments II | $300M | 1 | ||
7/18/2019 | Novalis LifeSciences Investments I |
Closing Date | 12/8/2021 | 7/18/2019 |
|---|---|---|
Fund | Novalis LifeSciences Investments II | Novalis LifeSciences Investments I |
Fund Type | ||
Status | ||
Amount | $300M | |
Sources | 1 |
Novalis LifeSciences Team
1 Team Member
Novalis LifeSciences has 1 team member, including current Managing Director, Devin Leake.
Name | Work History | Title | Status |
|---|---|---|---|
Devin Leake | Catalog Technologies, Sapir Venture Partners, Ginkgo Bioworks, Gen9, Thermo Fisher Scientific, Dharmacon, and Atugen | Managing Director | Current |
Name | Devin Leake |
|---|---|
Work History | Catalog Technologies, Sapir Venture Partners, Ginkgo Bioworks, Gen9, Thermo Fisher Scientific, Dharmacon, and Atugen |
Title | Managing Director |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.